COVID-19 Action for access

No patents or profiteering on drugs, tests, and vaccines in pandemic

Rationing because of high prices and insufficient supply will prolong pandemic

We call for no patents or profiteering on drugs, tests, or vaccines used for the COVID-19 pandemic.

MSF seeks to ensure that the medical tools urgently needed to respond to COVID-19 are accessible, affordable, and available to all countries equally.

All concerned stakeholders—including governments, pharmaceutical corporations, philanthropic organisations and research organisations developing treatments, diagnostics, and vaccines—should take the necessary measures to:

  • Ensure the rapid and ample production of medical tools, once approved, and allocate supply based on equity and need.
  • Prevent patents and monopolies from limiting production and affordable access.
  • Prioritise the availability of the medical tools for protection and treatment of frontline healthcare workers.
  • Improve transparency and coordination among governments and other buyers to monitor and mitigate supply chain risks.

We ask governments to prepare to suspend and override patents and take other measures, such as price controls, to ensure availability, reduce prices and save more lives; and to work in solidarity to meet not only their domestic needs but also to support other countries to get access to effective medicines, diagnostics, and vaccines.

We are also supporting MSF’s operational needs and priorities as we open new projects in response to COVID-19 and adapt existing ones to help cope if cases are identified. We are very concerned on how the COVID-19 pandemic will affect people in countries with already fragile health systems. Find out how we are responding to the pandemic around the world.

Overview: Access challenges to COVID-19 therapeutic candidates

This briefing document aims to provide an up-to-date snapshot analysis of the key access and supply challenges for selected promising candidate medicines.

Covid-19 Therapeutics Access Dashboard

What you can do to help

Support our recent activities by sharing on social media:

🌍 We made a public appeal calling for no patents or profiteering on COVID-19 medical tools, and urged governments to override patents to ensure availability, reduce prices, and save more lives

🌍 We asked governments to ensure that any future COVID-19 vaccines must be sold at cost and accessible to all

🌍🇪🇺 4th May - EU Commission Pledging Conference we are raising important questions about how the commitments made will be used and about the terms and conditions attached.

🇬🇧 We sent a letter asking the UK government to prevent Big Pharma profiteering from COVID-19.

🇺🇸 We sent and co-signed letters to Gilead Sciences expressing concerns about the corporation’s unacceptable approach to remdesivir, a potential COVID-19 drug.

🇪🇺  We sent and co-authored letters to the European Commission demanding EU research funding only be granted on condition that the final products are made affordable and accessible to everyone in need

🇺🇸 We joined UAEM's petition to US Secretary of Health and Human Services, Alex Azar asking that any vaccines and diagnostic tools for COVID19 developed with public funding in America will be made available to All

 

Stay updated

MSF Access brings down barriers that keep people from getting the treatment they need to stay alive and healthy. We advocate for effective drugs, tests and vaccines, that are affordable, available, suited to the people we care for and adapted to the places where they live

 

Follow our team

Our team has been taking a number of actions to ensure wide and equitable access to emerging treatments, tests, and vaccines so that no one is left behind.

Follow the Access Campaign and our team of experts on Twitter on potential treatments, diagnostics, and vaccines for COVID-19.

We know too well from our work around the world what it means to not be able to treat people in our care because a needed drug is just too expensive or simply not available

Dr Márcio da Fonseca
Infectious Disease Advisor
MSF’s Access Campaign